Biochemical markers and skeletal metastases
Biochemical markers and skeletal metastases
复制标题
DOI：
10.1097/01.blo.0000092979.12414.54
复制
发表时间：
2003-10-01
影响因子：
4.2
通讯作者：
Lipton, A
中科院分区：
文献类型：
--
作者：
Demers, LM;Costa, L;Lipton, A
双膦酸盐疗法用于治疗溶骨性转移的骨骼并发症已成为患有转移性骨疾病的癌症患者的标准治疗。评估患者对双膦酸盐治疗反应的能力得到了免疫测定的帮助，免疫测定可以测量溶骨性转移患者血液和尿液中增加的骨胶原分解产物。血液和尿液中羧基和氨基末端肽的测量特别有助于辅助方法，以促进骨转移患者的治疗。这些生化骨标志物已被证明与骨骼受累的程度相关，似乎提供了一种监测骨转移癌患者双膦酸盐治疗剂量和时间安排的方法。
Bisphosphonate therapy for the treatment of skeletal complications from osteolytic metastases has become standard care in patients with cancer who have metastatic bone disease. The ability to assess patient response to bisphosphonate therapy has been helped by the availability of immunoassays that can measure bone collagen breakdown products that are increased in the blood and urine of patients with osteolytic metastases. Measurements of the carboxy and amino terminal telopeptides in blood and urine particularly have been helpful as adjunct methods to facilitate the treatment of patients with skeletal metastases. These biochemical bone markers have been shown to correlate with the extent of skeletal involvement and seem to provide a means of monitoring the dose and scheduling of bisphosphonate therapy of patients with cancer who have bony metastases.